1. Selective BET bromodomain inhibition as an antifungal therapeutic strategy.
- Author
-
Mietton F, Ferri E, Champleboux M, Zala N, Maubon D, Zhou Y, Harbut M, Spittler D, Garnaud C, Courçon M, Chauvel M, d'Enfert C, Kashemirov BA, Hull M, Cornet M, McKenna CE, Govin J, and Petosa C
- Subjects
- Amino Acid Sequence, Animals, Antifungal Agents chemical synthesis, Azabicyclo Compounds chemical synthesis, Azabicyclo Compounds pharmacology, Azepines pharmacology, Benzodiazepines pharmacology, Binding Sites, Candida albicans growth & development, Candida albicans metabolism, Candida albicans pathogenicity, Candidiasis microbiology, Crystallography, X-Ray, Fungal Proteins chemistry, Fungal Proteins genetics, Gene Expression, Humans, Mice, Models, Molecular, Protein Binding, Protein Interaction Domains and Motifs, Protein Structure, Secondary, Pyridines chemical synthesis, Pyridines pharmacology, Recombinant Proteins chemistry, Recombinant Proteins genetics, Recombinant Proteins metabolism, Sequence Alignment, Sequence Homology, Amino Acid, Species Specificity, Transcription Factors chemistry, Transcription Factors genetics, Triazoles pharmacology, Antifungal Agents pharmacology, Candida albicans drug effects, Candidiasis drug therapy, Fungal Proteins antagonists & inhibitors, Molecular Targeted Therapy, Transcription Factors antagonists & inhibitors
- Abstract
Invasive fungal infections cause significant morbidity and mortality among immunocompromised individuals, posing an urgent need for new antifungal therapeutic strategies. Here we investigate a chromatin-interacting module, the bromodomain (BD) from the BET family of proteins, as a potential antifungal target in Candida albicans, a major human fungal pathogen. We show that the BET protein Bdf1 is essential in C. albicans and that mutations inactivating its two BDs result in a loss of viability in vitro and decreased virulence in mice. We report small-molecule compounds that inhibit C. albicans Bdf1 with high selectivity over human BDs. Crystal structures of the Bdf1 BDs reveal binding modes for these inhibitors that are sterically incompatible with the human BET-binding pockets. Furthermore, we report a dibenzothiazepinone compound that phenocopies the effects of a Bdf1 BD-inactivating mutation on C. albicans viability. These findings establish BET inhibition as a promising antifungal therapeutic strategy and identify Bdf1 as an antifungal drug target that can be selectively inhibited without antagonizing human BET function.
- Published
- 2017
- Full Text
- View/download PDF